YOLFTbeta
Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc

INO · NASDAQ · Healthcare / Biotechnology

1.43USD-0.03 (-2.05%)

Price History

Full chart

Market Stats

Previous Close1.46
Open1.44
Day Range1.39 – 1.48
52-Week Range0.56 – 2.72
Volume5.18M
Market Cap120.98M
P/E (TTM)0.00
Forward P/E16.58
EPS-1.02
Dividend Yield0.00%
Beta1.63
50-Day Avg1.10
200-Day Avg1.38

About

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jacqueline E. Shea Ph.D.
  • Employees112
  • Headquarters660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462, USA
  • Websitehttps://www.inovio.com

Leadership

  • Dr. Jacqueline E. Shea Ph.D.CEO, President & Director · b. 1966
  • Mr. Peter D. KiesChief Financial Officer · b. 1963
  • Dr. Michael Sumner B.S., M.B.A., M.D.Chief Medical Officer & Head of Development · b. 1965
  • Dr. Laurent M. Humeau Ph.D.Chief Scientific Officer & Chairman of the Scientific Advisory Board · b. 1967
  • Mr. Robert L. Crotty J.D.General Counsel, Corporate Secretary & Chief Compliance Officer · b. 1974
  • Ms. Jennie WillsonDirector of Communications
  • Mr. E. J. Brandreth MBASenior Vice President of Quality Assurance
  • Dr. Jeffrey Skolnik M.D.Senior Vice President of Clinical Development
  • Mr. Robert J. Juba Jr.Senior Vice President of Biological Manufacturing & Clinical Supply Management
  • Mr. Shawn D. Bridy M.A., M.B.A.Senior Vice President of Business Development

Financials

Income Statement

Currency: USD1998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue8.30M8.30M5.08M4.45M189.52K80.53K1.17M5.47M3.47M4.81M2.10M9.12M6.14M9.80M4.12M13.47M10.46M40.57M35.37M42.22M30.48M4.11M7.41M1.77M10.26M832.01K217.76K65.34K
Growth (%)-0.00%-38.83%-12.30%-95.74%-57.51%+1349.29%+368.45%-36.56%+38.62%-56.37%+334.78%-32.62%+59.41%-57.95%+226.98%-22.35%+288.00%-12.83%+19.37%-27.80%-86.51%+80.24%-76.05%+478.23%-91.89%-73.83%-69.99%
Cost of Revenue1.20M1.20M1.46M1.93M5.50M6.13M12.11M206.25K225.00K19.36M14.83M20.12M23.18M29.98M26.74M32.88M48.35M57.79M88.71M98.57M95.26M88.02M94.25M4.73M5.50M3.50M3.13M2.99M
Gross Profit7.10M7.10M3.62M2.53M189.52K80.53K1.17M5.26M3.24M4.81M2.10M9.12M6.14M9.80M4.12M13.47M10.46M40.57M35.37M42.22M30.48M4.11M7.41M1.77M10.26M832.01K-2.91M65.34K
Gross Margin85.54%85.54%71.29%56.77%100.00%100.00%100.00%96.23%93.51%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%-1337.41%100.00%
Operating Expense14.00M14.00M13.15M8.10M6.12M6.71M12.68M20.77M16.59M20.71M15.76M23.08M25.36M31.43M27.61M33.01M49.95M74.86M111.60M125.86M124.57M115.22M131.49M302.99M277.84M144.77M109.49M86.89M
Operating Income-6.90M-6.90M-9.53M-5.58M-5.93M-6.63M-11.51M-15.51M-13.35M-15.90M-13.66M-13.96M-19.22M-21.64M-23.49M-19.54M-39.50M-34.28M-76.24M-83.64M-94.09M-111.11M-124.08M-301.22M-267.57M-143.94M-112.40M-86.82M
Operating Margin-83.13%-83.13%-187.79%-125.22%-3131.53%-8237.11%-986.27%-283.63%-384.82%-330.68%-651.14%-153.04%-312.79%-220.91%-570.42%-145.12%-377.71%-84.50%-215.55%-198.11%-308.68%-2702.10%-1674.25%-16972.34%-2607.35%-17300.28%-51616.91%-132871.32%
EBITDA-8.97M-8.97M-8.37M-4.92M-5.28M-6.05M-10.94M-11.38M-12.43M-10.19M-11.97M-13.96M-17.11M-21.64M-22.65M-19.45M-37.93M-33.37M-74.15M-84.74M-89.80M-107.34M-149.56M-296.56M-270.90M-130.39M-103.95M-81.96M
EBITDA Margin-108.05%-108.05%-164.87%-110.50%-2787.69%-7511.39%-937.17%-208.07%-358.53%-211.88%-570.77%-153.04%-278.48%-220.91%-549.93%-144.39%-362.70%-82.24%-209.65%-200.70%-294.61%-2610.55%-2018.02%-16709.72%-2639.80%-15671.81%-47735.19%-125425.94%
Net Income-6.60M-6.60M-9.60M-8.87M-5.96M-4.66M-10.97M-15.30M-12.48M-11.20M-12.97M-24.41M-17.61M-15.25M-19.67M-66.03M-36.12M-29.19M-73.74M-88.21M-96.97M-119.36M-166.41M-303.66M-279.82M-135.12M-107.25M-84.95M
Net Income Margin-79.52%-79.52%-189.07%-199.11%-3147.32%-5792.83%-940.19%-279.79%-359.82%-233.05%-618.11%-267.67%-286.65%-155.72%-477.56%-490.29%-345.44%-71.94%-208.49%-208.92%-318.12%-2902.75%-2245.39%-17109.87%-2726.67%-16239.87%-49254.27%-130000.00%
R&D8.10M8.10M6.98M459.71K2.47M2.15M6.55M11.45M8.51M9.63M5.75M9.41M13.26M20.03M17.98M21.37M34.10M57.79M88.71M98.57M95.26M88.02M94.25M249.24M187.65M86.68M75.62M54.21M
R&D as % of Total Revenue97.59%97.59%137.42%10.32%1301.24%2666.01%561.10%209.52%245.37%200.22%274.14%103.16%215.74%204.51%436.67%158.67%326.06%142.44%250.82%233.47%312.51%2140.54%1271.66%14043.62%1828.55%10417.73%34727.10%82957.43%
Interest Expense24.34K24.34K24.34K20.38K5.45K20.48K03.33M03.42M49.01K10.50M1.51M34.28K4.93M88.17M3.36M5.18M139.25K25.93K346.09K7.95M8.70M1.94M1.25M1.22M177.83K0
Interest Expense % of Total Revenue0.29%0.29%0.48%0.46%2.87%25.43%0.00%60.90%0.00%71.17%2.34%115.17%24.52%0.35%119.74%654.71%32.09%12.76%0.39%0.06%1.14%193.30%117.42%109.11%12.22%146.97%81.67%0.00%

Balance Sheet

Currency: USD1998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets9.80M14.01M11.49M6.63M5.42M16.23M20.95M28.98M35.95M39.78M38.99M80.63M56.07M61.11M45.14M88.29M131.79M213.84M173.71M187.24M131.11M143.95M539.77M495.94M348.53M170.95M113.20M74.31M
Total Liabilities1.50M2.18M1.60M1.67M1.69M1.18M5.40M5.51M12.45M8.74M19.88M19.44M8.97M13.24M10.28M35.38M20.25M37.91M50.33M44.75M44.08M138.55M78.63M96.27M126.17M53.60M44.69M50.21M
Total Equity8.30M11.83M9.89M4.96M3.73M15.05M15.55M23.47M18.15M31.03M19.11M60.56M46.50M47.31M34.35M52.46M111.23M175.69M123.28M142.39M86.94M3.44M461.14M399.67M222.36M117.35M68.50M24.10M
Cash6.20M9.74M3.72M1.81M875.44K13.46M17.89M17.17M8.32M10.25M14.12M30.30M20.00M17.35M5.65M33.72M40.54M57.63M19.14M23.79M23.69M22.20M250.73M71.14M46.33M14.31M65.81M44.27M
Total Debt100.00K118.38K117.46K48.12K20.64K331.16K----12.11M12.11M---------99.51M39.05M33.02M32.07M30.21M11.87M9.37M
Net Debt-6.10M-9.62M-3.60M-1.76M-854.80K-13.13M-17.89M-17.17M-8.32M-10.25M-2.01M-18.18M-20.00M-17.35M-5.65M-33.72M-40.54M-57.63M-19.14M-23.79M-23.69M77.31M-211.68M-38.12M-14.25M15.90M-53.95M-34.91M

Cash Flow

Currency: USD1998-12-311999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-6.30M-6.30M-8.79M-8.37M-4.96M-2.75M-6.80M-12.34M-7.04M-11.51M-11.13M-14.08M-11.94M-19.76M-22.31M-15.38M-29.82M-12.44M-62.56M-63.21M-73.55M-97.85M-177.98M-215.71M-216.22M-124.37M-104.08M-88.63M
Investing Cash Flow--800.00K-785.09K-3.39M-389.15K-340.12K-439.12K-3.08M-16.07M-2.85M2.92M1.45M11.44M-10.90M5.28M-9.24M-35.81M-54.82M16.27M-27.83M42.42M-9.04M-58.80M-175.34M109.59M87.36M104.07M14.04M
Financing Cash Flow6.90M6.90M13.13M5.74M4.59M15.67M11.67M14.69M14.19M16.30M12.16M28.60M-9.69M28.01M5.33M52.69M72.46M84.35M7.79M95.69M31.04M105.40M465.28M211.50M81.84M5.00M51.48M53.05M
Capital Expenditure500.00K500.00K289.51K263.97K408.71K59.62K102.36K286.91K1.37M645.73K583.80K164.94K306.63K161.19K240.99K176.93K1.38M2.78M3.94M10.29M2.09M987.93K1.52M1.23M969.15K320.90K487.83K285.70K
Free Cash Flow-6.80M-6.80M-9.08M-8.63M-5.37M-2.81M-6.90M-12.63M-8.41M-12.16M-11.71M-14.25M-12.24M-19.92M-22.55M-15.56M-31.20M-15.22M-66.49M-73.50M-75.64M-98.84M-179.50M-216.94M-217.18M-124.69M-104.56M-88.92M
Dividends Paid------276.31K613.93K132.34K23.34K---0000000-93.24M3.86M-----
FCF to OCF107.94%107.94%103.29%103.15%108.24%102.17%101.51%102.33%119.38%105.61%105.25%101.17%102.57%100.82%101.08%101.15%104.63%122.36%106.30%116.29%102.83%101.01%100.85%100.57%100.45%100.26%100.47%100.32%
Dividend Paid to FCF-------4.00%-4.86%-1.57%-0.19%---0.00%0.00%0.00%0.00%0.00%0.00%0.00%--94.33%-2.15%-----

Earnings

Report DateMar 31, 2003Jul 16, 2003Nov 12, 2003Mar 30, 2004May 15, 2004Aug 12, 2004Nov 15, 2004Mar 15, 2005May 10, 2005Aug 9, 2005Nov 9, 2005Mar 16, 2006May 9, 2006Aug 8, 2006Nov 8, 2006Mar 16, 2007May 9, 2007Aug 8, 2007Nov 8, 2007Mar 17, 2008May 9, 2008Aug 7, 2008Nov 7, 2008Mar 31, 2009May 15, 2009Aug 19, 2009Nov 16, 2009Mar 29, 2010May 17, 2010Aug 13, 2010Nov 15, 2010Mar 17, 2011May 11, 2011Aug 5, 2011Nov 7, 2011Mar 15, 2012May 9, 2012Aug 9, 2012Nov 7, 2012Mar 18, 2013May 10, 2013Aug 9, 2013Nov 12, 2013Mar 17, 2014May 12, 2014Aug 11, 2014Nov 10, 2014Mar 16, 2015May 11, 2015Aug 10, 2015Nov 9, 2015Mar 14, 2016May 9, 2016Aug 8, 2016Nov 9, 2016Mar 15, 2017May 10, 2017Aug 8, 2017Nov 8, 2017Mar 14, 2018May 9, 2018Aug 7, 2018Nov 8, 2018Mar 12, 2019May 9, 2019Aug 8, 2019Nov 12, 2019Mar 12, 2020May 11, 2020Aug 10, 2020Nov 9, 2020Mar 1, 2021May 10, 2021Aug 9, 2021Nov 9, 2021Mar 1, 2022May 10, 2022Aug 9, 2022Nov 8, 2022Mar 1, 2023May 10, 2023Aug 9, 2023Nov 9, 2023Mar 6, 2024May 13, 2024Aug 8, 2024Nov 14, 2024Mar 4, 2025May 13, 2025Aug 12, 2025Nov 10, 2025Mar 13, 2026May 13, 2026Aug 12, 2026Nov 9, 2026
EPS Estimate----0.48-0.64-7.68-6.96-10.08-0.88-11.52-10.32-0.64-6.24-4.32-4.80-5.04-0.37-4.80-4.80-5.76-0.44-3.36-2.40-3.36--2.88-2.40-1.92-0.18-0.96-1.28-0.15-1.60-2.40-1.25-0.96-0.18-2.64-1.60-0.18-2.11-1.80-1.08-0.14-2.24-2.46-0.60-1.80-0.11-2.240.33-0.20-2.76-2.47-3.22-0.30-3.75-2.52-3.05-0.30-3.24-2.34-3.54-0.28-3.06-3.46-3.07-0.24-2.85-2.02-2.30-0.22-2.34-3.06-3.62-0.32-3.93-3.52-3.27-0.17-1.80-1.72-1.50-1.27-0.99-1.10-1.13-0.83-0.74-0.62-0.48-0.34-0.33-0.25-0.20
EPS Actual-14.75-5.31-29.51-0.48-0.40-5.76-10.08-10.56-0.88-5.76-8.16-2.40-4.32-4.80-5.28-7.20-0.44-5.28-5.282.40-0.28-4.32-2.40-4.32-3.78-2.88-3.36-0.96-0.08-3.36-0.48-0.28-0.91-0.96-1.92-2.16-0.24-1.44-2.52-0.02-2.88-2.88-7.68-0.28-2.40-2.28-1.44-1.44-0.17-1.080.96-0.26-1.32-3.12-3.36-0.35-3.72-1.56-4.68-0.23-4.32-0.84-3.24-0.35-3.60-3.60-2.76-0.38-3.12-9.96-2.76-0.14-3.24-4.68-3.48-0.50-4.32-5.52-1.80-0.21-1.92-1.56-1.56-1.12-1.31-1.19-0.89-0.60-0.51-0.61-0.87-0.28-0.31-0.07-
Surprise---0.00%37.50%25.00%-44.83%-4.76%0.00%50.00%20.93%-275.00%30.77%-11.11%-10.00%-42.86%-18.92%-10.00%-10.00%141.67%36.36%-28.57%0.00%-28.57%-0.00%-40.00%50.00%55.56%-250.00%62.50%-86.67%43.13%60.00%-53.60%-125.00%-33.33%45.45%-57.50%89.61%-36.49%-60.00%-611.11%-100.00%-7.14%7.32%-140.00%20.00%-54.55%51.79%190.91%-30.00%52.17%-26.32%-4.35%-16.67%0.80%38.10%-53.44%23.33%-33.33%64.10%8.47%-25.00%-17.65%-4.05%10.10%-58.33%-9.47%-393.07%-20.00%36.36%-38.46%-52.94%3.87%-56.25%-9.92%-56.82%44.95%-23.53%-6.67%9.30%-4.00%11.81%-32.32%-8.18%21.24%27.88%31.08%1.61%-81.25%19.59%6.06%72.00%-
Timing-----After-hoursPre-marketPre-market-After-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-Pre-marketAfter-hoursAfter-hours-After-hoursPre-marketPre-market-After-hoursPre-market-Pre-marketAfter-hoursPre-marketAfter-hours-After-hoursAfter-hours-After-hoursAfter-hoursPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap120.98M
Enterprise Value104.71M
Trailing P/E0.00
Forward P/E16.58
PEG Ratio0.00
Price / Sales961.51
Price / Book30.51
EPS-1.02
Book Value0.053
Revenue (TTM)0
Gross Profit (TTM)-48.49M
EBITDA-77.93M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-409.87%
Return on Assets-84.23%
Shares Outstanding103.40M
Shares Float95.79M
Beta1.63
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 5 analystsTarget 3.17
  • Strong Buy
    2
  • Buy
    1
  • Hold
    2

Ownership Breakdown

Institutions
46.01%
Insiders
0.33%
Retail / Other
53.66%

Top Institutional Holders

  • FMR Inc
    9.34M9.03%
  • HHG PLC
    3.31M3.20%
  • Vanguard Capital Management, LLC
    2.90M2.81%
  • Boxer Capital Management, LLC
    2.37M2.29%
  • ADAR1 Capital Management LLC
    1.47M1.42%
  • D. E. Shaw & Co LP
    1.35M1.31%
  • Two Sigma Investments LLC
    1.24M1.20%
  • Eversept Partners, LP
    1.04M1.00%
  • Geode Capital Management, LLC
    801.50K0.78%
  • Millennium Management LLC
    796.11K0.77%
  • BlackRock Inc
    662.18K0.64%
  • Renaissance Technologies Corp
    643.78K0.62%
  • Vanguard Fiduciary Trust Co
    392.07K0.38%
  • Northern Trust Corp
    298.87K0.29%

Top Fund Holders

  • Fidelity Small Cap Growth
    5.63M5.45%
  • Vanguard MStar Total Stk Mkt Idx Invest
    3.28M3.18%
  • Fidelity Small Cap Growth K6
    2.82M2.73%
  • A4Investments SICAV SIF ACCI IlanaA2EURH
    600.00K0.58%
  • Fidelity Extended Market Index
    398.40K0.39%
  • Abante Quant Value FI
    348.48K0.34%

Dividends

20174×
0.07Sep 28, 20170.07Aug 29, 20170.07Jul 27, 20170.07Jun 28, 2017

Stock Splits

  • Jan 25, 20241:12
  • Jun 6, 20141:4
  • Sep 13, 20041:4